Drug-Related Fever After Biologic Administration: Mechanisms, Clinical Features, and Management

Abstract

Drug-related fever is a significant and often underrecognized adverse effect associated with the administration of biologic agents. As the use of biologics continues to expand across diverse medical disciplines, understanding the epidemiology, mechanisms, risk factors, clinical manifestations, diagnostic approach, and management strategies for biologic-induced fever is essential for clinicians. This comprehensive review synthesizes current evidence, explores pathophysiological pathways, and discusses practical considerations and recent advances relevant to the clinical care of patients experiencing this phenomenon.

Introduction

The advent of biologic therapy has transformed the management of autoimmune, inflammatory, and oncologic diseases. Despite their targeted mechanisms, biologics are associated with a spectrum of adverse reactions, including drug-related fever. Fever following biologic administration poses diagnostic challenges, as it may mimic infection, disease flare, or infusion reaction, often resulting in extensive workup and therapy interruption. Accurate recognition and management of drug-related fever are critical to optimize therapeutic outcomes and minimize unnecessary interventions.

Epidemiology / Disease Burden

The incidence of drug-related fever after biologic administration varies depending on the class of biologic, patient population, and indication. Monoclonal antibodies (e.g., infliximab, rituximab) and fusion proteins have been most frequently implicated, with reported rates ranging from 1% to 10% in clinical trials. Real-world data suggest that up to 5% of patients on biologics may experience febrile episodes attributable to the drug itself. The burden is heightened in immunocompromised populations, where distinguishing drug fever from infection is particularly challenging, often leading to unnecessary hospitalizations, antibiotic use, and delays in disease management.

Pathophysiology

The mechanism of drug-related fever induced by biologics is multifactorial. Hypersensitivity reactions, cytokine release, and immune complex formation are principal contributors. Biologics can trigger both immediate and delayed immune responses, resulting in the release of pyrogenic cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α). This cytokine surge acts on the hypothalamic thermoregulatory center, leading to fever. Additionally, biologics may alter immune homeostasis, predisposing to nonspecific inflammatory responses or unmasking latent infections, further complicating the clinical picture.

Risk Factors

Identified risk factors for drug-related fever include prior hypersensitivity reactions, rapid escalation of biologic dosing, underlying autoimmune diseases, and concomitant use of other immunomodulatory agents. Patients with a history of multiple drug allergies or those receiving biologics for the first time are particularly susceptible. Genetic polymorphisms affecting cytokine regulation and immune response may also modulate individual risk, though data remain limited. Certain biologic classes, such as chimeric monoclonal antibodies, appear to carry a higher risk profile for febrile reactions.

Clinical Features

Drug-related fever typically manifests within hours to days following biologic administration, but delayed presentations are documented. Fever may be isolated or accompanied by constitutional symptoms such as malaise, chills, arthralgias, or mild rash. Severe reactions can present as part of a cytokine release syndrome (CRS), characterized by high-grade fever, hypotension, and multi-organ dysfunction. Unlike infectious fever, drug-related fever often lacks localized signs of infection or laboratory evidence of microbial etiology. Recurrence upon re-exposure to the offending agent is common and supports the diagnosis.

Diagnosis

The diagnosis of drug-related fever is one of exclusion and relies on thorough clinical assessment. A detailed drug history, temporal correlation with biologic administration, and exclusion of infectious, malignant, and autoimmune causes are essential. Laboratory findings are typically nonspecific, with mild leukocytosis or elevated acute-phase reactants. Blood cultures, imaging, and serological studies should be guided by clinical suspicion. Drug rechallenge or dechallenge may aid diagnosis but must be approached cautiously. Biomarkers such as procalcitonin may help differentiate bacterial infection from noninfectious fever in select cases.

Treatment & Management

Management is primarily supportive and involves discontinuation or temporary withholding of the suspected biologic. Antipyretics may provide symptomatic relief. In cases where the biologic is essential to disease control, careful risk-benefit assessment and desensitization protocols may be considered under specialist supervision. Severe reactions, such as cytokine release syndrome, require prompt intervention with corticosteroids, antihistamines, or specific cytokine inhibitors (e.g., tocilizumab for IL-6–mediated CRS). Education of patients regarding symptom recognition and prompt reporting is vital to minimize complications.

Recent Advances / Emerging Therapies

Recent advances focus on refining diagnostic differentiation between drug-related and infectious fever using molecular and proteomic biomarkers. Efforts to identify genetic susceptibility markers are underway, aiming to personalize biologic therapy and mitigate risk. The development of next-generation biologics with improved immunogenicity profiles may reduce the incidence of febrile reactions. Emerging therapies for severe cytokine-mediated fever include targeted cytokine blockade and novel immunomodulators, offering new avenues for management in refractory cases.

Guideline Recommendations

Current guidelines from professional bodies such as the American College of Rheumatology and the European Medicines Agency highlight the importance of vigilant monitoring for febrile reactions after biologic initiation. Recommendations include baseline infection screening, patient education on fever reporting, and structured algorithms for fever evaluation. In patients with suspected drug-related fever, guidelines advocate for prompt exclusion of infection, judicious use of antipyretics, and multidisciplinary decision-making regarding biologic continuation or discontinuation.

Conclusion

Drug-related fever after biologic administration remains a clinically significant entity that demands heightened awareness among healthcare professionals. Timely recognition, exclusion of alternative etiologies, and evidence-based management are paramount to ensuring patient safety and therapy continuity. Ongoing research into predictive markers and safer biologic agents holds promise for reducing the burden of this complication and optimizing patient outcomes in the era of precision medicine.